Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
84 hedge funds and large institutions have $191M invested in Eiger BioPharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 20 reducing their positions, and 9 closing their positions.
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
50% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 20
8% more funds holding
Funds holding: 78 → 84 (+6)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
13% less capital invested
Capital invested by funds: $220M → $191M (-$28.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$2.99M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$2.27M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.47M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.42M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$19M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$4.71M |
| 3 |
BC
Broadfin Capital
New York
|
-$3.13M |
| 4 |
TI
Telemetry Investments
New York
|
-$1.72M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.65M |
EIGR Hedge Fund Activity: Q3 2019 in Review
84 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q3 2019, worth a combined $191M — down 13% from $220M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new EIGR positions and 9 closed out — a net gain of 6 holders — while 30 added to existing stakes and 20 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $2.99M. The largest seller was Vivo Capital, exiting entirely with an estimated $19M sold.
- 84 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q3 2019, up from 78 in Q2 2019.
- Funds reported $191M of Eiger BioPharmaceuticals, Inc. stock for Q3 2019, down 13% quarter-over-quarter.
- 15 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q3 2019 and 9 closed out, a net change of +6 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q3 2019 was JP Morgan Chase, an estimated $2.99M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q3 2019 was Vivo Capital, an estimated $19M sold.
Based on aggregated 13F filings for Q3 2019.